Novo Nordisk(US:NVO) Zhi Tong Cai Jing·2025-07-29 13:54Group 1 - The company reported that the penetration rate of Wegovy in cash payment channels is lower than expected, primarily impacted by the ongoing effects of "unsafe and illegal mass-produced generics" [1] - The flagship diabetes drug Ozempic is facing increased competition in the U.S. market [1] - Analysts previously expected Novo Nordisk's annual sales growth to be 16.6% [1] Group 2 - On Tuesday, Novo Nordisk (NVO.US) opened with a drop of over 20%, reaching a two-and-a-half-year low of $54.60 [3] - The company issued a profit warning, significantly lowering its sales and operating profit growth forecasts for 2025, mainly due to underperformance in sales of the weight loss drug Wegovy [3] - The sales growth forecast, calculated at constant exchange rates, was revised down from 13%-21% to 8%-14%, while the operating profit growth forecast was adjusted from 16%-24% to 10%-16% [3]